Centene · MOUD Buprenorphine Subli · Medicaid MCO appeal

MOUD Buprenorphine Subli denied as duplicate or overlapping therapy by Centene?

Q: How long do I have to appeal a Centene MOUD Buprenorphine Subli denial?

Internal appeal window: 60 days from the date on the notice of action. External review window: State fair hearing — request typically within 90 days of the MCO's appeal decision. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-25

Medicaid MCO appeal

Cite: 42 CFR 438 Subpart F

Medicaid Managed Care Organization (MCO) denials are governed by federal Medicaid regulations and your state's Medicaid program rules. You have 60 days from the notice of action to file an internal appeal with the MCO. If the MCO upholds, you can request a state fair hearing — and importantly, you can request "aid pending appeal" (continued coverage during the review) if the appeal is filed within 10 days of the action.

Internal appeal window

60 days from the date on the notice of action

External review window

State fair hearing — request typically within 90 days of the MCO's appeal decision

What Centene typically requires

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

Source policy: Centene/Envolve Medicaid Buprenorphine PA

What works in the appeal

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

The Centene angle on MOUD Buprenorphine Subli

## Why Centene Issued This Denial

Centene's "duplicate therapy" denial for sublingual buprenorphine (MOUD) typically means their pharmacy system detected another opioid or opioid-partial-agonist claim on file for the same member within the same coverage period — most often another buprenorphine product (such as a film vs. tablet formulation), a concurrent methadone claim through a different benefit, or an old claim that has not yet closed in the system.

This denial is almost always a billing or records mismatch rather than a clinical determination that the medication is inappropriate. It is highly appealable.

## Why This Denial Is Appealable

If there is no true duplicate — meaning only one buprenorphine MOUD product is being prescribed and dispensed — the denial rests on an administrative error in Centene's claims data and should be overturned on the first internal appeal with the right supporting documentation. If a concurrent claim does exist, the appeal should clarify the clinical rationale for the specific product selected and confirm the other claim is no longer active.

MHPAEA parity law also applies: Centene cannot apply a duplicate-therapy restriction to MOUD that is more burdensome than it applies to analogous chronic condition treatments.

## Federal Appeal Framework

Internal appeal (Level 1): File within the timeframe on the denial letter. Centene must respond within 30 days (standard) or 72 hours (expedited/urgent).
External review (ACA §2719 / ERISA §503): Available after exhausting internal appeals — generally within four months of the final internal denial. An IRO will review whether the duplicate-therapy determination was accurate.
Expedited review: Request if delayed treatment would jeopardize health or treatment stability.

## Concrete Appeal Steps

1. Request Centene's claim data showing exactly which claims triggered the duplicate flag — ask for EOB detail and the specific claim dates. 2. Confirm with your pharmacy and prescriber that only one buprenorphine MOUD product is active. 3. If a prior claim is still open in Centene's system, work with the pharmacy to close or reverse it. 4. Have the prescriber submit a brief letter confirming the single prescribed product and that no true duplicate therapy is occurring. 5. If the appeal is denied internally, proceed to external review.

## Documentation to Gather

Explanation of Benefits showing the duplicate-flagged claims
Prescriber's letter confirming only one MOUD product is prescribed and clinically indicated
Pharmacy dispensing records confirming no duplicate fills
Prior claims reversal documentation (if applicable)

## Criteria-Mapping Structure

| Centene Duplicate-Therapy Criterion | Supporting Evidence | |---|---| | No concurrent active claim for same or equivalent therapy | Pharmacy records + prescriber confirmation letter | | Only one MOUD product prescribed | Prescription records from the treating clinician | | Prior overlapping claim closed/reversed (if applicable) | Pharmacy reversal documentation or EOB correction |

Next steps

Look at the date on the "notice of action" — the 60-day clock starts there.
If you file within 10 days, request "aid pending appeal" to keep coverage during the review.
Submit the internal appeal in writing using the form on the MCO's denial letter.
If denied, request a state fair hearing — the form is on your state Medicaid agency's website.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other insurers on MOUD Buprenorphine Subli

Aetna denied as duplicate or overlapping therapy of MOUD Buprenorphine Subli

Other denial reasons for Centene MOUD Buprenorphine Subli

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on 42 CFR 438 Subpart F. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.